Dr. Judith Jones, MD., Ph.D., President and CEO of the Degge Group, Ltd., a drug safety research company, says, "Drug safety is front and center on the public health radar screen, and iGuard provides a unique, patient-centered solution in real-time."
iGuard is a wholly owned subsidiary of Quintiles Transnational Corp. and is the fastest and easiest way for patients to get information and safety updates on the drugs they are taking. This drug safety monitoring program facilitates bi-directional exchange of timely and relevant information, enabling patients to take an active role in managing their health. iGuard maintains an efficient communication channel where patients and health professionals can monitor, evaluate and share information about drug risks and benefits. Registration is free online at http://www.iguard.org.
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
biotechnology and healthcare industries. With 19,000 employees and offices
in more than 50 countries, it is focused on providing customer-centric
solutions that are the gold standard of the industry. For more information,
please visit the company's Web site at http://www.qtrn.com.
Available Topic Expert(s): For information on the listed expert(s), click
Copyright©2007 PR Newswire.
All rights reserved